Ignite Creation Date:
2024-05-06 @ 2:41 AM
Last Modification Date:
2024-10-26 @ 11:22 AM
Study NCT ID:
NCT02104011
Status:
COMPLETED
Last Update Posted:
2018-01-23
First Post:
2014-04-01
Brief Title:
Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers
Sponsor:
University Hospital Bordeaux
Organization:
University Hospital Bordeaux
Study Overview
Official Title:
Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers Pilot Trial
Status:
COMPLETED
Status Verified Date:
2018-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STBETA
Brief Summary:
Treatment of angiomyolipomas is based on invasive techniques such as surgery or embolization Development of anti-angiogenic therapies is a major and growing field of research in hypervascularized tumors Angiomyolipomas have been shown to regress after prolonged treatment with mTOR inhibitors Sirolimus but with a large proportion of secondary effects We showed recently that beta-blockers were able to induce regression of infantile hemagiomas Consequently we looked for and found histologically in a few cases of angiomyolipomas the presence of beta2 receptors
The aim of the study is to estimate if beta-blockers could induce regression or stabilization of renal angiomyolipomas in tuberous sclerosis in a pilot study
The aim of the study is to estimate if beta-blockers could induce regression or stabilization of renal angiomyolipomas in tuberous sclerosis in a pilot study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None